finance.yahoo.com

Tempus AI shares rise as Personalis Phase 3 trial hits endpoint

Tempus AI logoTempus AI
Sig3.25Sen+4.10Env0.00Soc0.00Gov0.00
Moderna logoModerna
Sig3.60Sen+3.80Env0.00Soc+1.60Gov0.00

Phase 3 INTerpath-001 results show intismeran autogene (V940) plus Keytruda met the recurrence-free survival endpoint, supporting Personalis’ personalized cancer vaccine platform built on ImmunoID NeXT. The Tempus deal is paid entirely in Tempus stock, with a possible up to 50% cash option. Tempus also reported higher MRD testing volumes and the clinical win bolsters the acquisition’s strategic case, though it doesn’t confirm economics.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro